RESUMO
BACKGROUND/AIM: Prostate cancer (PCa) is the second most commonly diagnosed cancer in men. In contrast to localized disease, metastatic PCa leads to increased mortality. Kisspeptin (KISS1) functions as a metastasis suppressor in various cancers. The aim of this study was to detect the expression of KISS1 and its receptor GPR54 (KISS1R) in prostate cancer. MATERIALS AND METHODS: The expression of KISS1 and KISS1R was examined in prostate cancer tissue specimens after radical prostatectomy. RESULTS: A higher expression of KISS1 and KISS1R was shown in patients with localized tumors (Stage ≤IIb) compared to patients with advanced (Stage ≥III) tumor. High Gleason score PCa and higher prognostic groups patients showed a lower expression rate of both KISS1 and KISS1R. CONCLUSION: A down-regulation of KISS1-KISS1R system was detected in advanced prostate cancer. KISS1as tumor suppressor might be useful in the future for the diagnosis, risk assessment of prostate cancer progression, as well as a therapeutic target for aggressive tumors.
Assuntos
Kisspeptinas/biossíntese , Neoplasias da Próstata/metabolismo , Receptores de Kisspeptina-1/biossíntese , Idoso , Humanos , Imuno-Histoquímica , Kisspeptinas/metabolismo , Masculino , Pessoa de Meia-Idade , Gradação de Tumores , Estadiamento de Neoplasias , Neoplasias da Próstata/genética , Neoplasias da Próstata/patologia , Receptores de Kisspeptina-1/genética , Receptores de Kisspeptina-1/metabolismoAssuntos
Recidiva Local de Neoplasia/cirurgia , Neoplasias Ureterais/cirurgia , Neoplasias da Bexiga Urinária/cirurgia , Urotélio/patologia , Veia Cava Inferior/anormalidades , Idoso , Humanos , Masculino , Recidiva Local de Neoplasia/patologia , Ultrassonografia , Ureter/irrigação sanguínea , Neoplasias Ureterais/patologia , Neoplasias da Bexiga Urinária/patologia , Veia Cava Inferior/diagnóstico por imagemRESUMO
Herein, we report on our experience with six patients (0.3%) diagnosed with lymphoepithelioma-like bladder carcinoma (LELBC) over the past 15 years at our department. The mean age of the patients with LELBC was 73 years (range 69-80 years). All patients had at least pT2 disease. The primary treatment was transurethral resection of the bladder tumor, radical cystectomy (RC), and radiotherapy (RT) in one, two, and three patients, respectively. After a mean follow-up of 31 months (range 13-72 months), three patients are still alive. The predominant subtype was diagnosed in four patients, three of whom are alive at the time of writing, compared with the two patients in whom the focal subtype was diagnosed, both of whom are dead. Two of the living patients were treated with a bladder-preservation strategy. Our experiences suggest that RC may not be necessary in muscle invasive disease and that RT and chemotherapy may be reliable treatment options. The pathology report may be useful in selecting patients suitable for bladder-preservation treatment.
Assuntos
Carcinoma/patologia , Linfócitos do Interstício Tumoral , Neoplasias da Bexiga Urinária/patologia , Idoso , Feminino , Humanos , Masculino , Estudos RetrospectivosRESUMO
Neuroendocrine small cell carcinoma of the urinary tract is rarely encountered and very few cases have been reported in the literature. Herein we describe a case of small cell malignancy located contemporarily in the ureter and the bladder.